Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2025-12-28 @ 4:33 PM
Study NCT ID:
NCT04425135
Status:
UNKNOWN
Last Update Posted:
2020-06-11
First Post:
2020-06-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
OBU-ALKNSCLC-IIT-SHR1210-APA-C
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None